Author

Liyi Geng

Observed name: L. Geng

Institution: Mayo Clinic

Observed institutions: University of Science and Technology of China, Mayo Clinic, Anhui Provincial Hospital

ORCID: 0009-0009-8040-1915

Observed ORCID: 0009-0009-8040-1915

OpenAlex ID: A5085729992

A Phase I Trial of Nab-Paclitaxel/Bevacizumab (AB160) Nano-Immunoconjugate Therapy for Gynecologic Malignancies

2024 · Eleftheria Kalogera, Wendy K. Nevala, et al. · Clinical Cancer Research · 21

PD-L1-Targeting Nanoparticles for the Treatment of Triple-Negative Breast Cancer: A Preclinical Model

2025 · Wendy K. Nevala, Liyi Geng, et al. · International Journal of Molecular Sciences · 4

P1106: Preliminary Results of a Phase 1 Study of Novel Bcl-2 Inhibitor Lisaftoclax (apg-2575) in Chinese Patients (pts) With Relapsed or Refractory (r/r) Non-hodgkin Lymphomas (nhls)

2022 · M. Sun, J. Qi, et al. · HemaSphere · 1

Supplementary Table S1 from A Phase I Trial of Nab-Paclitaxel/Bevacizumab (AB160) Nano-Immunoconjugate Therapy for Gynecologic Malignancies

2024 · Eleftheria Kalogera, Wendy K. Nevala, et al.

Data from A Phase I Trial of Nab-Paclitaxel/Bevacizumab (AB160) Nano-Immunoconjugate Therapy for Gynecologic Malignancies

2024 · Eleftheria Kalogera, Wendy K. Nevala, et al.

Supplementary Figure S1 from A Phase I Trial of Nab-Paclitaxel/Bevacizumab (AB160) Nano-Immunoconjugate Therapy for Gynecologic Malignancies

2024 · Eleftheria Kalogera, Wendy K. Nevala, et al.

Supplementary Table S1 from A Phase I Trial of Nab-Paclitaxel/Bevacizumab (AB160) Nano-Immunoconjugate Therapy for Gynecologic Malignancies

2024 · Eleftheria Kalogera, Wendy K. Nevala, et al.

Supplementary Figure S2 from A Phase I Trial of Nab-Paclitaxel/Bevacizumab (AB160) Nano-Immunoconjugate Therapy for Gynecologic Malignancies

2024 · Eleftheria Kalogera, Wendy K. Nevala, et al.

Supplementary Figure S1 from A Phase I Trial of Nab-Paclitaxel/Bevacizumab (AB160) Nano-Immunoconjugate Therapy for Gynecologic Malignancies

2024 · Eleftheria Kalogera, Wendy K. Nevala, et al.

Data from A Phase I Trial of Nab-Paclitaxel/Bevacizumab (AB160) Nano-Immunoconjugate Therapy for Gynecologic Malignancies

2024 · Eleftheria Kalogera, Wendy K. Nevala, et al.

Supplementary Figure S2 from A Phase I Trial of Nab-Paclitaxel/Bevacizumab (AB160) Nano-Immunoconjugate Therapy for Gynecologic Malignancies

2024 · Eleftheria Kalogera, Wendy K. Nevala, et al.

Works count: 11

Citation count: 26

H-index: 2

I10-index: 1